13th Aug 2014 09:28
LONDON (Alliance News) - Cambridge Cognition Holdings PLC said Wednesday it has expanded its partnership with Altreos Research Partners Inc after the release of two draft US Food and Drug Administration guidelines on human-abuse liability assessments on drugs and abuse-deterrent products.
The company said that the new partnership plans to capitalise on increased demand for ways to assess the human-abuse potential of new chemical entities. Under the partnership, the two will develop and supply scientific software to identify potential cognitive impairment caused by new chemical entities, and identify new abuse-deterrent products.
Cambridge said Altreos had already helped with the development of its newly launched "cloud" abuse liability product CTIS-AL. Altreos will continue to provide support for the product, and its consulting services will now be accessible by Cambridge clients.
No financial details of the agreement have been disclosed.
Shares in Cambridge Cognition are untraded Wednesday; it last closed at 55.50 pence.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Cambridge Cog